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 Uveal melanoma is the most common intraocular tumor
in adults and is associated with high mortality [1]. Over the
past several decades, many advances have been made in terms
of prognostic efficiency and treatment modalities, resulting in
a reduction in patient morbidity [2]. Current prognostic meth-
ods rely on histopathological profiling of tumor sections de-
rived from enucleations with prognostic markers including cell
type, tumor size, and a mean of the 10 largest nucleoli [3].
More recently, prognosis has been inferred independently of
traditional histopathological markers. For example, poor prog-
nosis has been linked to chromosome 3 aberrations [4]. In
addition, employment of radiation therapy in the treatment of
uveal melanoma has largely replaced enucleation for smaller
tumors thus sparing the orbit in many cases [2]. Despite these
advances, mortality rates remain unchanged. Approximately
50% of uveal melanoma patients will die within 10 years from
metastasis, which localizes predominantly to the liver [1,5].
Due to the lack of lymphatics in the eye, uveal melanoma
spreads almost exclusively via hematogenous dissemination
[5]. Current understanding of this neoplasm is based on infor-
mation gathered from studies focusing either on primary tu-
mors or their corresponding metastases. However, very little
is known about tumor cells subsequent to their egress from
the ocular environment and before their development in the
liver. Malignant cells are thought to disseminate from the pri-
mary tumor early in tumorigenesis and remain in a clinically
latent state until either the cells themselves or the host is re-
ceptive to the development of metastases [6]. The biologic
activity of these circulating malignant cells (CMCs) remains
unclear. However, evidence from this laboratory, which is
based on microarray analysis of tumor cells derived from dif-
ferent a stages of the metastatic cascade in an animal model,
has demonstrated distinct changes in gene expression as cells
progress from the eye to the blood and to the liver [7]. Such
evidence highlights the importance of further characterization
and understanding of CMCs.
CMCs have been detected in several malignancies includ-
ing breast cancer and cutaneous melanoma [8,9]. CMCs have
also been detected in uveal melanoma by the polymerase chain
reaction (PCR) in a clinical trial conducted at this laboratory
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Purpose: Uveal melanoma (UM) is the most common intra-ocular tumor in adults. Despite advances in diagnosis and
treatment, the survival rate of UM has not increased in the last several decades. Approximately 50% of patients will die as
a consequence of metastatic disease with the majority of metastases localized to the liver. Due to the lack of lymphatics in
the eye, hematogenous dissemination is the predominant means by which UM cells escape the primary site. Our labora-
tory has recently demonstrated the presence of circulating malignant cells (CMCs) in the blood using both animal models
and clinical trails involving UM patients. Current data suggests that all UM patients will be positive for CMCs after
diagnosis. Furthermore, some of the phenotypic changes that are necessary for metastatic growth may occur while the
cells are circulating in the blood. In this study, we evaluated the efficiency of a panel of antibodies to immunomagnetically
isolate CMCs for the purpose of in vitro expansion and genetic, immunological, and phenotypic characterization.
Methods: In this study, five human uveal melanoma cell lines (92.1, MKT-BR, OCM-1, SP6.5, and UW-1) were
immunostained with a panel of antibodies against known melanoma cell surface markers. Staining with monoclonal
antibodies PAL M2, NKI C3, NKI/Beteb, and 9.2.27 permitted the generation of a cell surface expression profile in these
cell lines. The five human UM cell lines and 92.1 transfected with GFP were subsequently spiked into human blood at
concentrations ranging from 1x106 cells/ml to 10 cells/ml. Cells were immuno-magnetically isolated at concentrations as
low as 10 cells/ml.
Results: Immunomagnetic isolation of all five human UM cell lines tested at concentrations down to 10 cells/ml human
blood was achieved only when antibodies were used in combination. Individually, the antibodies did not permit isolation
of cells at physiologically relevant concentrations.
Conclusions: The immunomagnetic isolation method presented in this study can be used to isolate CMCs at physiologi-
cally relevant concentrations and at sensitivities comparable to those seen in polymerase chain reactions (PCR). In addi-
tion, our data suggests that our method is more efficient and reliable for the isolation of CMCs in UM than the methods
currently used.
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50[10]. While PCR is a valuable method for the detection of
CMCs, it is not without its limitations. In addition to the vari-
ability associated with the sensitivity of CMC detection re-
ported in the literature, it does not permit the genotypic or
phenotypic characterization of malignant cells in the blood.
The mere presence of CMCs in uveal melanoma patients does
not appear to be of prognostic value. PCR identification of
CMCs in uveal melanoma suggests that all patients become
positive at some point during the disease progression despite
the fact that only 50% will die. Thus, CMC positivity may not
be an inherent predictor of the clinical outcome of uveal mela-
noma [10].
Immunomagnetic isolation of CMCs from uveal mela-
noma patients may circumvent the limitations associated with
PCR. Such a technique could enable the isolation of viable
neoplastic cells that could then be subjected to any downstream
application. As a result, CMCs could be subjected to the same
scrutiny currently reserved for primary tumors or their me-
tastases such as the establishment of cell cultures and geno-
typic and phenotypic characterization. Such studies could po-
tentially shed light on the clinical implications connected to
CMC positivity in uveal melanoma. Immunomagnetic isola-
tion of CMCs from solid tumors has been demonstrated in a
variety of malignancies including colorectal cancer, breast
carcinoma, osteosarcoma, cutaneous, and uveal melanoma
[9,11-13]. However, the current application of this emerging
technology in the characterization of uveal melanoma may be
incomplete. Current CMC isolation relies on the use of a single
antibody, which may result in an underestimation in the sensi-
tivity of the technique. In our method, we examine both inde-
pendently and in combination a panel of antibodies reported
to bind antigens expressed on uveal melanoma cells for their
ability to efficiently capture CMCs at physiologically relevant
concentrations [14].
METHODS
Cell culture:  The human uveal melanoma cell lines 92.1,
SP6.5, and MKT-BR were established by Dr. Jager (Univer-
sity Hospital Leiden, Leiden, The Netherlands), Dr. Pelletier
(Laval University, Quebec, Canada), Dr. Belkhou (CJF
INSERM, Strasbourg, France), respectively. Dr. Albert (Uni-
versity of Wisconsin-Madison, Madison, WI) established the
OCM-1 and UW-1 cell lines [15,16].
The five human uveal melanoma cell lines were incubated
at 37 °C in a humidified 5% CO2-enriched atmosphere. All
cell lines were cultured in RPMI-1640 medium (Invitrogen,
Burlington, Ontario, Canada), supplemented with 5% heat
inactivated fetal bovine serum (FBS; Invitrogen), 1%
fungizone (Invitrogen), and 1% penicillin-streptomycin
(Invitrogen). Cells were fed bi-weekly, and the nonadherent
28SC cells were centrifuged at every feeding. 92.1, MKT-BR,
OCM-1 SP6.5, and UW-1 were grown to confluence as a
monolayer and passaged by treatment with 0.05% trypsin in
EDTA (Fisher, Whitby, Ontario, Canada).
Green fluorescent protein transfection:  Uveal melanoma
cell line 92.1 was transfected with green fluorescent protein
(GFP) using lipofectamine as per the manufacturer’s instruc-
tions (Promega, Invitrogen). Briefly, 2 µg of GFP was diluted
in 100 µl OPTI-MEM serum-free medium. Cells were allowed
to incubate overnight at 37 °C in a 5% CO2 environment. Cells
were then grown in selective growth medium with 400 µg/ml
G418 (Gibco, Ontario, Canada). Fluorescence was checked
weekly using an inverted epi-fluorescent microscope (Nikon,
Ontario, Canada).
Cytospins:  Cytospins were prepared from lines 92.1,
MKT-BR, OCM-1, SP6.5, and UW-1 at a concentration of
250,000 cells/spin (Shandon Scientific, Cheshire, England).
Cytospins were fixed in paraformaldehyde and stored at -20
°C until needed.
Immunocytochemistry:  Immunostaining was performed
on cytospins of lines 92.1, MKT-BR, OCM-1, SP6.5, and UW-
1 according to the avidin-biotin complex technique. Blocking
of non-specific binding was performed by incubating samples
in a Tris buffer containing 1% bovine serum albumin (TBS/
1% BSA). Cytospins were incubated for 1 h at room tempera-
ture with one of the murine monoclonal antibodies NKI/Beteb
(melanoma-associated antigen 100 kDa, 7 kDa), NKI/C3
(melanoma-associated antigen), or PAL-M2 (determinant dis-
criminating nevo cellular nevi, malignant melanoma) diluted
1:100 as indicated by the manufacturer (Monosan, Uden, The
Netherlands). Negative controls incubated without a primary
antibody were included for each cytospin tested.
Immunostaining was performed on paraformaldehyde-
fixed cytospins of lines 92.1, MKT-BR, OCM-1, SP6.5, and
UW-1 cell lines using the primary antibody 9.2.27 (purified
mouse anti-chondroitin sulfate monoclonal antibody; BD Bio-
sciences PharMingen, Franklin Lakes, NJ) using the Envision
system-AP (DakoCytomation, Carpinteria, CA). Negative
controls incubated with mouse sera were included for each
cytospin tested.
Isolation of uveal melanoma cells from culture:  Uveal
melanoma cells were isolated using the CELLection Pan
Mouse IgG Kit (Dynal Biotechnology, Oslo, Norway) con-
sisting of 4.5 µm superparamagnetic polystyrene beads coated
with monoclonal human anti-mouse IgG. Cells were isolated
via the direct technique as described by the manufacturer. Uveal
melanoma cell lines 92.1, MKT-BR, OCM-1, SP6.5, UW-1,
and 92.1, transfected with GFP, were adjusted to a concentra-
tion of 1x106 cells/ml in phosphate buffered saline (PBS) con-
taining 0.1% BSA, and five 10 fold dilutions were performed
to yield six cell concentrations ranging from 1x106 to 10 cells/
ml PBS/0.1%BSA. Cell suspensions from lines 92.1, OCM-
1, and SP6.5 were added to CELLection Pan Mouse IgG
Dynabeads pre-labeled with NKI/C3, NKI/Beteb, PAL-M2,
or the combination of all three antibodies. Cell suspensions
consisting of the remaining cell lines were added to
CELLection Pan Mouse IgG Dynabeads pre-labeled with NKI/
C3and NKI/Beteb in combination. Negative controls consisted
of cells incubated with unlabeled beads. Cells were then eluted
and plated in six-well plates containing 1 ml RPMI-1640 me-
dium supplemented with 5% heat-inactivated FBS, 1%
fungizone, and 1% penicillin-streptomycin. Cultures were
monitored daily for growth via microscopic evaluation.
Isolation of uveal melanoma cells from spiked human
©2008 Molecular Vision Molecular Vision 2008; 14:50-5 <http://www.molvis.org/molvis/v14/a6/>
51blood:  Uveal melanoma cells were isolated via the direct tech-
nique using the CELLection Pan Mouse IgG Kit as described
by the manufacturer. Human uveal melanoma cell lines 92.1,
MKT-BR, OCM-1, SP6.5, UW-1, and 92.1 transfected with
GFP were adjusted to a concentration of 1x106 cells/ml PBS/
0.1% BSA and five 10 fold serial dilutions were performed to
yield six cell concentrations ranging form 1x106 to 10 cells/
ml of PBS/0.1% BSA. Cell suspensions were mixed with an
equal volume of blood obtained from healthy volunteers.
Mononuclear cells (MNCs) and CMCs were isolated using
Ficoll Paque Plus. The washed, pelleted MNCs and CMCs
were resuspended in PBS/0.1% BSA and incubated with
CELLection Pan Mouse IgG Dynabeads pre-labeled with ei-
ther a combination of monoclonal antibodies, NKI/C3 and
NKI/Beteb, or 9.2.27. Negative controls consisted of cells in-
cubated with unlabeled beads. Bound cells were eluted and
plated in six-well plates containing 1 ml RPMI-1640 medium
supplemented with 5% heat-inactivated FBS, 1% fungizone,
and 1% penicillin-streptomycin. Cultures were monitored daily
for growth via microscopic evaluation. All human blood
samples for these experiments were obtained as per the IRB
approved protocol.
RESULTS
Immunocytochemical profile of the five human uveal mela-
noma cell lines:  The immunocytochemical staining profile
for lines 92.1, MKT-BR, OCM-1, SP6.5, and UW-1 is depicted
in Table 1. Immunostaining was graded subjectively as nega-
tive (-), low (+), moderate (++), and high (+++) as previously
described by Makitie, Summanen et al. [17]. Three indepen-
dent observers performed these evaluations based on the over-
all impression of the cytospins, which were examined under a
light microscope at magnifications of 100x-400x. All cytospins
stained positive using NKI/C3 with SP6.5 showing the lowest
levels of expression (+; Figure 1). By contrast, all other cell
lines exhibited moderate staining intensity (++) with this anti-
body (Figure 1). Staining patterns associated with NKI/Beteb
were all moderate (++) except for UW-1, which was low (-).
All cytospins demonstrated moderate levels of staining for
PAL-M2 (++). Three cell lines displayed a high staining in-
tensity (+++) with 9.2.27 with the exceptions of 92.1 and SP6.5.
SP6.5 displated negative (-) levels of 9.2.27 expression as
depicted in Figure 1. The 92.1 cell line displayed low levels
(+) of staining intensity.
Isolation of uveal melanoma cells from culture:
Immunomagnetic isolation of uveal melanoma cells from cul-
ture was used to validate our method and determine its sensi-
tivity in our uveal melanoma cell lines. The three uveal mela-
noma cell lines used to initially validate our method were 92.1,
OCM-1, and SP6.5 because of their observed immunocy-
tochemical profile. Initially, CELLection Dynabeads were pre-
labeled with NKI/C3 only. This permitted the capture of cells
at concentrations of 1x106 to 10 cells/ml PBS/0.1% BSA for
OCM-1 and SP6.5 but not 92.1. Capture of cells at a concen-
tration of 10 cells/ml PBS/0.1% BSA is comparable to the
reported sensitivity of nested PCR observed in the literature
[13]. Pre-labeling of Dyanbeads with only NKI/C3 failed to
capture 92.1 at a concentration lower than 1x102 cells/ml PBS/
0.1% BSA.
In an attempt to improve the efficiency of
immunomagnetic isolation of uveal melanoma cells,
Dynabeads were pre-labeled with both NKI/C3 and NKI/
Beteb. This combination of antibodies enabled the capture of
all six cell lines down to a concentration of 10 cells/ml PBS/
0.1% BSA. Pre-labeling of Dynabeads with a combination
NKI/C3, NKI/Beteb, and PAL-M2 together failed to increase
the sensitivity of the assay and actually prevented the isola-
tion of 92.1, OCM-1, and SP6.5 below a concentration of 1x103
cells/ml PBS/0.1% BSA. This observation in combination with
the observation that NKI/C3 used alone is insufficient to per-
mit the capture of 92.1 (which showed low staining intensity
in 92.1) at concentrations comparable to those observed using
PCR resulted in the omission of PAL-M2 from future assays.
In all cases, cells at concentrations of 1x106 to 1x104 cells/
ml PBS/0.1% BSA were immediately discernable by light mi-
croscopy after performing the assay. Conversely, definitive
identification of viable uveal melanoma cells at concentra-
tions of 1x103 to 10 cells/ml PBS/0.1% BSA was only pos-
sible after approximately five days of incubation at 37 °C in a
humidified 5% CO2-enriched atmosphere.
Isolation of uveal melanoma cells from spiked human
blood:  Subsequent to validation and optimization of the
immunomagnetic isolation method in culture, samples of blood
from healthy volunteers were spiked with 92.1, MKT-BR,
OCM-1, SP6.5, UW-1, or 92.1 transfected with GFP. Initially,
blood samples were spiked with 92.1 transfected with GFP.
This permitted easy identification of melanoma cells and their
discrimination from other cell types present in the MNC layer
as depicted in Figure 2A,B. In addition, this enabled us to
identify a time frame in which we could expect to detect growth
of melanoma cells at different concentrations.
Immunomagnetic isolation from washed MNC layers using
Dynabeads pre-labeled with monoclonal antibodies, NKI/
Beteb and NKI/C3, permitted the capture of all five cell lines
from a concentration range of 1x106 to just 10 cells/ml human
blood.
Immunomagnetic isolation of cell lines, 92.1, MKT-BR,
SP6.5, and 92.1 transfected with GFP, from washed MNC lay-
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TABLE 1. IMMUNHISTOCHEMICAL STAINING PROFILE FOR FIVE HUMAN
UVEAL MELANOMA CELL LINES
                 Antibody/staining intensity
            ------------------------------------
Cell Line   PAL-M2   NKI/C3   NKI/beteb   9.2.27
---------   ------   ------   ---------   ------
92.1          ++       ++        ++         +
SP6.5         ++       +         ++         -
MKT-BR        ++       ++        ++        +++
OCM-1         ++       ++        ++        +++
UW-1          ++       ++         +        +++
Immunhistochemical staining profile for the five human uveal mela-
noma cell lines 92.1, MKT-BR, OCM-1, SP6.5, and UW-1 using
monoclonal antibodies NKI/C3, NKI /Beteb, PAL-M2, and 9.2.2.7
as determined by three independent observers.
52ers using Dynabeads pre-labeled with monoclonal antibody
9.2.27 permitted the capture of 92.1, MKT-BR, and 92.1 trans-
fected with GFP from a concentration of 1x106 to 10 cells/ml
human blood. SP6.5 could not be captured at a concentration
below 1x106 cells/ml human blood.
Cells at concentrations of 1x106 to 1x105 cells/ml human
blood were immediately detectable by light microscopy after
performing the isolation assay. Conversely, cells at concen-
trations of 1x104 cells/ml human blood were only detectable
by light microscopy within five to seven days of incubation at
37 °C in a humidified 5% CO2-enriched atmosphere.
DISCUSSION
 The observation that nearly all uveal melanoma patients will
test positive for the presence of CMCs over the course of their
disease challenges the traditional concept of tumor progres-
sion. It would stand to reason that since only 50% of UM pa-
tients will die from metastasis, only a subset of patients would
test positive for CMCs and that this would serve as a predictor
for the development of metastases at a later date [1]. This does
not appear to be the case. Thus, CMC positivity in itself is not
an inherent predictor of metastasis in uveal melanoma and in
itself, not of prognostic value. Studies in which
immunomagnetic isolation of CMCs in cutaneous and uveal
melanoma was used to quantify the presence of CMCs in blood
and bone marrow concluded that the number of CMCs de-
tected could be used to predict patient outcome [13,18]. In
addition, some inherent properties of the CMCs themselves
may offer insight into the propensity of a particular cell to
form metastases, eventually leading to patient mortality.
Emerging evidence has challenged the notion that meta-
static ability is a product of mutation and selection, which
occurs in the late stages of tumorigenesis. Rather, the muta-
tions associated with the emergence of a particular neoplasm
confer its potential for metastasis with metastatic capability
acquired early on in development [19,20]. Evidence support-
ing this hypothesis is abundant. In breast cancer, genetic sig-
natures of poor prognosis observed in the primary tumor are
highly predictive of patient outcome. In addition, studies have
demonstrated the maintenance of global expression profiles
between primary tumors and distant metastases [21].
Immunomagnetic isolation of CMCs in patients with cu-
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Figure 1. Immunohistochemical profile of 5 human uveal melanoma cell lines stained with monoclonal antibodies.  Immunohistochemical
profile of 5 human uveal melanoma cell lines (92.1, SP6.5, MKT-BR, OCM-1, and UW-1) stained with monoclonal antibodies PAL M2, NKI
C3, NKI/Beteb, 9.2.27, and appropriate negative control. Each image is at 400x magnification.
53taneous or uveal melanoma has revealed clonal relatedness
between isolated cells with a population of cells demonstrat-
ing genetic profiles associated with poor prognosis. For ex-
ample, patients with poor prognosis also had UM cells that
exhibited monosomy of chromosome 3 [13]. Collectively, these
results suggest that distinct populations of cells may have a
predetermined capability to give rise to metastasis and that
this potential can be identified before seeding of the meta-
static site. The cell lines employed in this study all have known
metastatic potentials as demonstrated in an animal model of
uveal melanoma (UM) [22]. The detection of poor prognosis
expression profiles in CMCs could be very useful in identify-
ing patients at risk for the development of metastasis.
Further evidence suggests that in addition to a poor prog-
nostic profile, tumors capable of metastasis possess sub-popu-
lations of cells, which exhibit tissue specific metastatic gene
expression profiles [20]. Kang et al. [23] demonstrated the
existence of distinct metastases gene expression profiles
present in breast cancer cells that metastasize to the bone and
of those which metastasize to the adrenal medulla. Cell popu-
lations shown to be highly metastatic to the bone were en-
riched in vivo, and it was found that the metastatic behavior
was not associated with an increased expression of poor prog-
nosis genes but with the upregulation of specific metastasis
gene-expression profiles comprising of cell surface or secreted
proteins. Similarly, Kakiuchi et al. [24] identified candidate
genes that may be involved in organ specific metastasis in
small cell lung cancer. Thus, in addition to genes indicative of
poor prognosis, a distinct subset of genes exist which are re-
lated to the specifics of metastasis [23].
Initial data from this laboratory has similarly demonstrated
changes in expression profiles of UM cells as they progress
from the environment of the eye through the blood and the
liver in an animal model of uveal melanoma. If identified in
uveal melanoma, such genes could be useful in the classifica-
tion of patients at risk for the development of metastasis as
well as produce potential therapeutic targets. Immunomagnetic
isolation of CMCs could therefore be extremely useful in the
enrichment of such cell populations from patients.
Immunomagnetic isolation of CMCs from patients with
various malignancies including colorectal cancer, breast car-
cinoma, osteosarcoma, cutaneous, and uveal melanoma has
been demonstrated at sensitivities comparable to PCR [9,11-
13,18]. However, in the latter case, the isolation of CMCs is
performed using only the monoclonal antibody 9.2.27 [13].
Immunohistochemical profiling of our uveal melanoma cell
lines revealed that the expression of a given cell surface pro-
tein is not necessarily consistent between different cell lines.
Thus, an observation of high staining intensity with a given
antibody on a particular cell line does not suggest an identical
result in a different cell line. Our results therefore argue against
the use of a single antibody for widespread application of CMC
immunomagnetic isolation from uveal melanoma patients.
Results clearly indicated that isolation of 92.1 using only NKI/
C3 was inefficient and that to approach physiologically rel-
evant sensitivity, a combination of NKI/C3 and NKI/Beteb
had to be used. This combination of antibodies was found to
be sufficient to permit the isolation of all cell lines tested at
concentrations down to 10 cells/ml human blood. This result
is significant as it has been postulated that disseminated tu-
mor cells in patients without clinical metastases are present at
very low frequencies (10-5-10-6) in bone marrow and lymph
node [25].
The method for the isolation of circulating, cutaneous,
and uveal melanoma cells outlined in the literature uses beads
labeled with the 9.2.27 antibody alone [8,18]. Our results dem-
onstrated that 9.2.27 used alone is insufficient to capture SP6.5
below a concentration of 1x106 cells/ml whole human blood.
Thus, use of this antibody alone may result in certain popula-
tions of circulating cells escaping detection. The question as
to which combination of antibodies represents an optimum
efficiency for the capture of CMCs remains unresolved. How-
ever, labeling with three antibodies does not appear to be more
beneficial than labeling with two. In fact, our results suggest
that it may actually hinder the isolation efficiency. The use of
three antibodies failed to isolate 92.1, OCM-1, and SP6.5 at
concentrations below 1x103 cells/ml PBS/0.1% BSA
To the best of our knowledge, this is the first study to
assess the efficiency of a panel of antibodies in their ability to
permit immunomagnetic isolation of CMCs in uveal mela-
noma and the first study in North America to attempt to
immunomagnetically isolate UM cells from blood. The initial
results presented suggest that this method can be used to iso-
late CMCs at physiologically relevant concentrations and at
sensitivities comparable to those seen in nested PCR. In addi-
tion, our data suggests that our method is more efficient and
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Figure 2. View of 92.1 cells isolated
from spiked human blood.  A: View
at 10x magnification using conven-
tional light microscopy of a colony of
92.1 transfected with GFP isolated
from a sample of spiked human blood
at a concentration of 10 cells/ml. B:
View at 10x magnification using
phase contrast microscopy of the
colony of 92.1 transfected with GFP
depicted in A isolated from a sample
of spiked human blood at a concen-
tration of 10 cells/ml.
54reliable for the isolation of CMCs in uveal melanoma than
those methods currently in use. In addition, CMC isolation in
an established animal model of uveal melanoma will permit
further validation of this technique, providing a strong indica-
tion of the value of this method and its potential for use in a
clinical setting.
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